| Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. | |
| | |
MedLine Citation:
|
PMID: 16116042 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Hypertension in blacks is more prevalent and less often controlled than the hypertension of other ethnic groups. We sought to explore the benefit of adding inhibitors of the epithelial sodium channel (ENaC), an aldosterone-regulated site of sodium reabsorption in the distal nephron, to the antihypertensive regimen of black hypertensive patients. In a prospective, randomized, placebo-controlled, double-blind clinical trial, we used a 2-by-2 factorial design with 4 treatment groups: amiloride (a direct inhibitor of ENaC), spironolactone (an aldosterone receptor antagonist), the combination of both drugs, and placebo. The subjects (n=98) had an elevated blood pressure despite treatment that included a diuretic and a calcium channel blocker; the level of plasma renin activity was < or =0.56 ng/L per second. The primary end points were changes from baseline in systolic and diastolic blood pressure over a 9-week period of treatment. The reductions in systolic and diastolic blood pressures (mm Hg) were, respectively, 9.8+/-1.6 (SE) and 3.4+/-1.0 for amiloride (P<0.001) and 4.6+/-1.6 (P=0.006) and 1.8+/-1.0 for spironolactone (P=0.07). Treatment with either amiloride or spironolactone or the combination was well tolerated; no patient experienced hyperkalemia. In a substudy, plasma endothelin-1 levels were observed to decrease after 3 weeks of treatment with spironolactone (P<0.001), consistent with a non-ENaC-related potential benefit of spironolactone. In conclusion, treatment with either amiloride or spironolactone can provide an additional reduction in blood pressure in blacks already receiving conventional antihypertensive therapy. |
| | |
Authors:
|
Chandan Saha; George J Eckert; Walter T Ambrosius; Tae-Yon Chun; Mary Anne Wagner; Qianqian Zhao; J Howard Pratt |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review Date: 2005-08-22 |
Journal Detail:
|
Title: Hypertension Volume: 46 ISSN: 1524-4563 ISO Abbreviation: Hypertension Publication Date: 2005 Sep |
Date Detail:
|
Created Date: 2005-08-26 Completed Date: 2005-12-13 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 7906255 Medline TA: Hypertension Country: United States |
Other Details:
|
Languages: eng Pagination: 481-7 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
African Continental Ancestry Group* Amiloride / therapeutic use Blood Pressure / drug effects* Epithelial Sodium Channel Humans Hypertension / drug therapy, ethnology*, physiopathology* Sodium Channel Blockers / therapeutic use* Sodium Channels / drug effects* Spironolactone / therapeutic use |
| Grant Support | |
ID/Acronym/Agency:
|
M01-RR00750/RR/NCRR NIH HHS; R01-HL-3579/HL/NHLBI NIH HHS; R01-HL6730/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Epithelial Sodium Channel; 0/Sodium Channel Blockers; 0/Sodium Channels; 2609-46-3/Amiloride; 52-01-7/Spironolactone |
| Comments/Corrections | |
Comment In:
|
Hypertension. 2005 Sep;46(3):469-70
[PMID:
16116049
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Electromagnetic fields affect transcript levels of apoptosis-related genes in embryonic stem cell-de...
Next Document: Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity.